Tenaya Therapeutics Shares Updates Related To Its Ongoing Phase 1b/2 MyPEAK-1 Clinical Trial Of TN-201; TN-201 Has Appropriate Tolerability Profile At 3E13 vg/kg Dose Without Unexpected Adverse Reactions
Portfolio Pulse from Benzinga Newsdesk
Tenaya Therapeutics provided updates on its Phase 1b/2 MyPEAK-1 clinical trial for TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy. The therapy shows appropriate tolerability at the tested dose, with no unexpected adverse reactions. Initial data from Cohort 1 is expected in December.
October 17, 2024 | 8:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tenaya Therapeutics' TN-201 shows promising tolerability in its Phase 1b/2 trial for hypertrophic cardiomyopathy, with no unexpected adverse reactions. Initial data from Cohort 1 is anticipated in December, which could impact stock prices.
The update on TN-201's tolerability and the absence of unexpected adverse reactions is positive news for Tenaya Therapeutics. The anticipation of initial data in December could lead to increased investor interest and potential stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100